Rare mutation may explain healthier aging in long-lived families

A rare mutation in a DNA-sensing gene has emerged as a fresh clue to why some families seem to age more slowly than others. In a study of 212 long-lived sibship groups, researchers narrowed their search from roughly 20,000 genes to about 350 candidates across four genomic regions, then identified 12 rare protein-altering variants in seven genes.

The standout finding mapped to cGAS, short for cyclic GMP-AMP synthase, and appeared in two long-lived families. That matters because cGAS sits inside immune and inflammatory signaling, where too much activity can help drive chronic inflammation, yet too little may leave the body more vulnerable to infection and cancer. The new result does not point to a single longevity switch. It instead strengthens a healthier-aging view of exceptional lifespan, one in which modest protective effects may help people stay disease-free longer.

The work was presented at the European Society of Human Genetics conference in Gothenburg, Sweden, and adds another layer to the Leiden Longevity Study, one of the most closely watched family-based aging cohorts in Europe. The Dutch project recruited about 420 long-lived families between 2002 and 2006, along with more than 1,700 offspring and about 740 partners, giving investigators a large multigenerational dataset to compare family members who age unusually well with their relatives.

That lineage of research has already shown a pattern. Earlier findings from the same group found that middle-aged offspring of long-lived parents developed cardiometabolic disease about 13 years later than peers whose parents lived shorter lives. A 2023 Nature Communications study went further, reporting that having more long-lived ancestors was associated with up to a decade of additional healthspan. Together, those results suggest that exceptional longevity often arrives with delayed disease onset and more favorable immune-metabolic profiles, not just extra years on the calendar.

Researchers including Pasquale Putter, Eline Slagboom and Joris Deelen are now trying to determine exactly how the cGAS variant works and how common it is. The broader implication is clear: longevity research is moving away from the search for one miracle gene and toward the idea that multiple small biological advantages, layered over a lifetime, may help families age with less inflammation, less disease and more years of good health.